EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study

Capucine Baldini, Philippe A Cassier, Jean-Pierre Delord, Matteo Simonelli, Mehdi Touat, Lili Yao, J Paul Duic, Alexander Gozman, Aurelien Marabelle

Journal of Neuro-Oncology · 2026-04 · 177 (2)

DOI: 10.1007/s11060-026-05461-2 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 01.04.2026. Verfasst von Capucine Baldini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U1015/…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glioma, Microsatellite Instability, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGliomaMicrosatellite InstabilityBrain NeoplasmsNeoplasm Recurrence, LocalDNA Mismatch RepairAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedAdultAgedFollow-Up Studies

Stichwörter der Autor:innen

DNA mismatch repairGliomaMicrosatellite instabilityPembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U1015/CIC1428, Université Paris-Saclay, Villejuif, France. capucine.baldini@…
  • Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, Villejuif, 94800, France. capucine.baldini@gustaveroussy.fr.
  • Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Université de Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • IRCCS Humanitas Research Hospital, Rozzano, Italy.

Zitieren

APA

Baldini, C., Cassier, P. A., Delord, J. P., Simonelli, M., Touat, M., Yao, L., Duic, J. P., Gozman, A., & Marabelle, A. (2026). Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study. Journal of Neuro-Oncology, 177(2). https://doi.org/10.1007/s11060-026-05461-2

Vancouver

Baldini C, Cassier PA, Delord JP, Simonelli M, Touat M, Yao L, et al. Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study. Journal of Neuro-Oncology. 2026;177(2). doi:10.1007/s11060-026-05461-2

BibTeX
@article{Baldini2026,
  author = {Baldini, Capucine and Cassier, Philippe A and Delord, Jean-Pierre and Simonelli, Matteo and Touat, Mehdi and Yao, Lili and Duic, J Paul and Gozman, Alexander and Marabelle, Aurelien},
  title = {Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  volume = {177},
  number = {2},
  doi = {10.1007/s11060-026-05461-2}
}
Kostenlos starten →